News & Press Releases

All
  • All
  • Blog
  • Bowel Cancer
  • Case Study
  • Chemotoxicity
  • Colorectal Cancer
  • News
  • Personalised Medicine
  • Press Release
Graph

Colorectal cancer in the Covid-19 era

Istock 916407356

Launching the 5FU Test Alliance

C0377390

OCB are presenting today with IBM at Pharmatec19 – London Room 7 at 11:20: Using AI Technology To Improve Outcomes For Cancer Patients

Istock 819568470

Oxford Cancer Biomarkers appoints a Medical Science Liaison Manager to strengthen operations and support continued growth

Pawel Wolyniec

Oxford Cancer Biomarkers hires two Senior Operations and Quality Control Specialists to help manage continued growth

James Otter

OCB appoints James Otter as new CEO

Ocb Logo

Oxford Cancer Biomarkers Ltd. and Oxford University Hospitals offer genetic testing to prevent 5-FU/capecitabine toxicity

PRESS RELEASE: Oxford, UK and South Korea, 3rd June 2019: KwangDong Pharmaceutical Co. Ltd and Oxford Cancer Biomarkers Ltd. agree a significant investment partnership

Chongqing Uni2

Dr Kevin Xu, Chief Software Engineer, speaks at Chongqing and Henan Universities, China.

Rebeccas Tattoo

Rebecca survived the toxic effects of 5-FU against the odds. This is her story, in her words.

OCB and Meridian IT video explains ColoProg advances

OCB’s ColoPredict provides an accurate colorectal cancer screening that patients can trust